Alnylam Pharma (ALNY) Tops Q1 EPS by 4c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $143.71 -0.06%
Revenue Growth %: +33.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +33.0%
Financial Fact:
Net loss: -90.13M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.62), $0.04 better than the analyst estimate of ($0.66). Revenue for the quarter came in at $18.51 million versus the consensus estimate of $15.4 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Employers Holdings (EIG) Misses Q1 EPS by 2c
- Universal Logistics Holdings, Inc. (ULH) Tops Q1 EPS by 136c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
